Navigation Links
Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
Date:1/29/2009

CHADDS FORD, Pa., Jan. 29 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today that by mutual agreement it has concluded its research collaboration with Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) to develop an inhaled fentanyl product for the treatment of breakthrough pain using Alexza's Staccato(R) inhalation technology. The product, Staccato(R) fentanyl (AZ-003/EN-3284), has completed Phase I clinical testing and will be returned to Alexza. In 2007, Endo licensed exclusive rights to develop and commercialize AZ-003 in North America.

Ivan Gergel, M.D., Endo's executive vice president of research and development, stated: "As a result of our ongoing strategic review initiated last year, we have terminated certain research and development programs. We have enjoyed working with Alexza and wish them success with their drug development programs. In the meantime, we remain committed to building our pipeline by pursuing programs at all phases of development, including potential products arising from our virtual discovery program."

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain i
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 The Pulmonary Fibrosis ... data from more than 1,100 patients and families suffering ... Drug Administration (FDA) for the Patient-Focused Drug Development Meeting ... a new FDA initiative to seek patient input in ... therapeutic treatments. "We applaud the FDA for ...
(Date:9/16/2014)... , Sept. 16, 2014 Astellas announced ... of Business Communications & Advocacy, Urology in the ... Communications & Advocacy Margaret Long. In this role, Noland ... urology to patient and advocacy organizations, as well ... key strategic initiatives. Noland,s appointment is the latest ...
(Date:9/16/2014)... 2014  Aratana Therapeutics, Inc. (NASDAQ: ... licensing, developing and commercializing innovative biopharmaceutical products for ... an underwritten registered public offering of shares of ... being offered by Aratana Therapeutics. ... book-running managers for the offering.  ...
Breaking Medicine Technology:PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 2PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 3PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 4Christy Noland to Lead Urology Advocacy and Communications for Astellas 2Aratana Therapeutics, Inc. Announces Proposed Public Offering 2
... Oct. 11 Merial, the Animal Health division ... ), announced today that Merial Animal Health Co. (China) held ... located in the Nanchang Hi-tech Development Zone, China. Merial ... the Group,s first production facility in China has been in ...
... , EXTON, Pa., Oct. 9 Kensey Nash Corporation (Nasdaq: ... earnings results for its first quarter ended September 30, 2009 ... , Joe Kaufmann, President and CEO, will be ... 22, 2009 at 9:00 A.M. Eastern Time. , ...
Cached Medicine Technology:Merial invests US $70 million in Nanchang, China 2Merial invests US $70 million in Nanchang, China 3Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference 2
(Date:9/16/2014)... 2014 The second federal bellwether trial ... Johnson subsidiary Ethicon concluded with the jury in the ... awarding her $3.27 million in damages, according to a ... “jurors found Ethicon liable for selling faulty devices and ... were at risk from side effects that include pain, ...
(Date:9/16/2014)... 16, 2014 Advanced Fertility Center of ... by Houstonia Magazine as one of the Top Doctors ... Magazine - a metropolitan magazine serving the Houston area. ... recognize them for their outstanding services. This accomplishment will ... of Houstonia Magazine — a special publication listing all ...
(Date:9/16/2014)... Duke’s Chowder House Lake Union is ... and Gratafy for a fun evening of tech networking. ... cemented. With the growth of companies in these sectors, there’s also ... work in tech and at startups to connect with each other. ... to host events for their peers to meet and mingle in ...
(Date:9/16/2014)... radiation therapy as part of breast conservation is ... hormone-receptor positive (HR+) invasive breast cancer. A new ... however, shows that combination may not be necessary ... , The results, which Fox Chase researchers presented ... Annual Meeting on Sunday, September 14, suggest that ...
(Date:9/16/2014)... This year’s theme is centered around entrepreneurism ... Mills, Pennsylvania, September 15, 2014- Holganix, an elite member ... growing companies in the country, produces an organic Bionutritional ... health-care by naturally decreasing disease and insect damage though ... that it will hold its third annual Bionutritional Summit ...
Breaking Medicine News(10 mins):Health News:Ethicon to Appeal Bellwether Trial Verdict of $3.27 Million, Rottenstein Law Group LLP Notes 2Health News:Dr. Michael Allon Receives Esteemed Recognition 2Health News:Seattle Seafood Restaurant Duke’s Chowder House Partners with Rebls & Gratafy for Tech Networking Happy Hour Event. 2Health News:Seattle Seafood Restaurant Duke’s Chowder House Partners with Rebls & Gratafy for Tech Networking Happy Hour Event. 3Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:Holganix Holds 3rd Annual Bionutritional Summit in Louisville, Kentucky 2
... Steven Reinberg HealthDay Reporter , MONDAY, March ... second of three reactors at earthquake-ravaged Japan,s Fukushima Dai-ichi ... the facility were safe, according to news reports. ... with seawater after Friday,s devastating earthquake and tsunami knocked ...
... major study of the wellbeing and inclusion of former ... by Queen,s University today (Monday 14 March). ... in Northern Ireland and the border region of Ireland ... of loyalist and republican former prisoners (aged 50 and ...
... Researchers at Georgia Health Sciences University are studying whether ... metabolite could halt the progression of diabetic nephropathy, or ... year, $308,000 grant from the American Heart Association, Dr. ... College of Dental Medicine and Pharmacology and Toxicology in ...
... International Liver CongressTM is an opportunity for over ... to hear the latest research, perspectives and treatments ... field. It features a high-calibre and multi-disciplinary scientific ... the most essential topics. EASL will hold ...
... taken by certain women as a preventive measure against breast ... conclusion of a new study published early online in ... The study,s results suggest that the benefits of tamoxifen to ... post-menopausal women under age 55 years who have an increased ...
... to resist the targeted drug Herceptin, but a single ... vulnerability to treatment, scientists at The University of Texas ... Nature Medicine . Adding the drug saracatinib to ... at least five different molecular pathways, each of which ...
Cached Medicine News:Health News:Explosion Rocks 2nd Nuclear Reactor in Japan 2Health News:Explosion Rocks 2nd Nuclear Reactor in Japan 3Health News:Explosion Rocks 2nd Nuclear Reactor in Japan 4Health News:Report into well-being and inclusion of former politically motivated prisoners 2Health News:Report into well-being and inclusion of former politically motivated prisoners 3Health News:International Liver Congress 2011 2Health News:Taking tamoxifen to prevent breast cancer can save lives and money 2Health News:Combination overcomes breast cancer resistance to herceptin 2Health News:Combination overcomes breast cancer resistance to herceptin 3
... Digisonics is a web-based application to securely ... cardiovascular modalities. Users can login from ... password to review stored patient studies. ... patient information, images, and reports Quickly locates ...
... stands for Stainless Steel Kleener. SSK-80 is ... and stain remover for ultra-sonic cleaners. , ... of your instruments by removing and inhibiting ... pivot points, box joints and moving instrument ...
... Foam is the ready-to-use, pre-cleaning enzymatic foam ... ,Hemaway Enzymatic Foam sprays on ... It's perfect for use in the O.R. ... Getting a head start with Hemaway Enzymatic ...
... Cytospin has been synonymous with ... More than 15,000 laboratories worldwide ... It provides economical thin-layer preparations ... hypocellular fluids such as spinal ...
Medicine Products: